Amyloidosis
A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.
Subtype terms (4)
More specific conditions that are subtypes of Amyloidosis in the MeSH hierarchy.
- Amyloid Neuropathies
4 drugs (2 approved, 2 experimental)
- Amyloidosis, Familial
12 drugs (9 approved, 3 experimental)
- Cerebral Amyloid Angiopathy
8 drugs (4 approved, 4 experimental)
- Immunoglobulin Light-chain Amyloidosis
59 drugs (43 approved, 16 experimental)
Drugs by status
Approved for this indication (4)
Phase 4 trials (1)
Phase 3 trials (22)
Phase 2 trials (34)
- venetoclax
- bendamustine
- carfilzomib
- selinexor
- elotuzumab
- gemcitabine
- miridesap
- gsk2398852
- idelalisib
- hyaluronidase (human recombinant)
- ibrutinib
- Isatuximab
- Ursodoxicoltaurine
- vinorelbine
- l-epigallocatechin
- dobutamine
- dapagliflozin
- daratumumab
- pomalidomide
- amiodarone
- dexamethasone
- belantamab mafodotin
- Lisaftoclax
- Eplontersen
- gc012f
- linvoseltamab
- teclistamab
- zn-d5
- cm336
- at-02
- +4 more
Phase 1 trials (21)
Organizations
Organization Involved with Phase 4 Indications (8)
Organization Involved with Phase 3 Indications (38)
- Foldrx
- Eisai
- Millennium Pharmaceuticals
- Pfizer
- Biogen
- Novartis
- Alexion
- Alnylam Pharmaceuticals
- Bellus Health Inc
- C.T. Development America, Inc.
- GlaxoSmithKline
- Ionis Pharmaceuticals, Inc.
- National Cancer Institute (NCI)
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute on Aging (NIA)
- Boston University
- European Myeloma Network
- Nanjing University
- Seoul National University
- University of Pavia
- Mayo Clinic
- Food and Drug Administration
- Covance
- Optum
- University of Limoges
- Medpace, Inc.
- National Taiwan University
- Prothena Biosciences Inc
- Fortress Biotech
- Akcea Therapeutics
- +8 more
Organization Involved with Phase 2 Indications (53)
- Spectrum Pharmaceuticals
- Celgene
- Cephalon
- Bristol-Myers Squibb
- Gilead Sciences
- Grifols
- Bayer
- Oncopeptides AB
- Piramal
- SOM Biotech SL
- PETHEMA Foundation
- National Institutes of Health (NIH)
- Medical Research Council
- University Hospital Heidelberg
- Cancer and Leukemia Group B (CALGB)
- Chang Gung University
- University of London
- Cornell University
- Eastern Cooperative Oncology Group
- Temple University
- University of Washington
- Hellenic Cooperative Oncology Group
- Herbert Irving Comprehensive Cancer Center
- Hoosier Cancer Research Network
- Southwest Oncology Group
- Tufts University
- University of Heidelberg
- University of Iowa
- University of Tennessee
- University of Toronto
- +23 more
Organization Involved with Phase 1 Indications (14)
Organization Involved with Other Experimental Indications (13)
- AbbVie
- National Heart, Lung, and Blood Institute (NHLBI)
- American Heart Association
- Centre Hospitalier Universitaire de Nīmes
- Nanjing Medical University
- Stanford University
- Capital Medical University
- Peking University
- Soochow University
- University of Ulsan
- State University of New York, Buffalo
- University of Nice Sophia Antipolis
- People's Liberation Army of China